# Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

> **NCT06890182** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed

## Key facts

- **NCT ID:** NCT06890182
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890182, "Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06890182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*